Chien-Feng Chen

Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial.

K. Swedberg, M. Gheorghiade, F. Zannad, 2009, European heart journal.

An open‐label, unit dose‐finding study of AMG 531, a novel thrombopoiesis‐stimulating peptibody, in patients with immune thrombocytopenic purpura

J. Christal, M. Kappers-Klunne, J. Zwaginga, 2006, British journal of haematology.

AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP.

J. George, J. Nieva, J. Bussel, 2006, The New England journal of medicine.

A Multiple‐Dose, Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Group QT/QTc Study to Evaluate the Electrophysiologic Effects of THC/CBD Spray

E. Sellers, P. Duncombe, Chien-Feng Chen, 2013, Clinical pharmacology in drug development.

Safety Profile of AMG 531 in Healthy Volunteers and in Thrombocytopenic Patients with Immune Thromobocytopenic Purpura.

J. Christal, Chien-Feng Chen, D. Stepan, 2005 .

Long-Term Dosing of AMG 531 Is Effective and Well Tolerated in Thrombocytopenic Patients with Immune Thrombocytopenic Purpura.

J. George, J. Nieva, J. Bussel, 2005 .

An Open-Label, Unit Dose-Finding Study Evaluating the Safety and Platelet Response of a Novel Thrombopoietic Protein (AMG531) in Thrombocytopenic Adult Patients (Pts) with Immune Thrombocytopenic Purpura (ITP).

Chien-Feng Chen, A. Newland, B. Varet, 2004 .

A Phase 2 Placebo Controlled Study Evaluating the Platelet Response and Safety of Weekly Dosing with a Novel Thrombopoietic Protein (AMG531) in Thrombocytopenic Adult Patients (pts) with Immune Thrombocytopenic Purpura (ITP).

J. Nieva, J. Bussel, L. Aledort, 2004 .